Bone marrow samples from 30 patients with myelodysplastic syndromes (MDS) grouped according to the International Prognostic Scoring System for MDS were investigated for counts of microvessels, total metachromatic mast cells (MC) and MC expressing tryptase, an angiogenesis-inducing molecule. Counts were higher in patients with a poor prognosis. The observation of a high correlation between microvessel counts and both total metachromatic and tryptase-reactive MC in all samples suggests that angiogenesis in MDS increases with their progression and that MC may intervene in the angiogenic response in MDS through tryptase contained in their secretory granules.
Introduction
Tumor angiogenesis is uncontrolled and unlimited in time. It is essential for a tumor's growth, invasion and metastasis during the transition from the avascular to the vascular phase. 1 Increased angiogenesis has been documented in a wide variety of hematopoietic malignancies that include acute lymphoblastic leukemia (ALL) in childhood, B cell leukemia, adult myeloblastic leukemia, acute promyelocytic leukemia, chronic lymphocytic leukemia, myelofibrosis, myelodysplasia and myeloproliferative disorders, such as polycythemia vera (reviewed in Ref. 2) . Neoangiogenesis has also been studied in myeloma, 3, 4 where it was found to be increased in proportion to plasma cell infiltration.
Increased microvascular density in the bone marrow of patients with myelodysplastic syndromes (MDS) 5, 6 has been described. Korkopipoulou et al 7 have recently demonstrated that this density is intermediate between that of controls and acute myeloid leukemia.
Tumor cells are surrounded by an infiltrate of inflammatory cells, namely lymphocytes, neutrophils, macrophages and mast cells (MC), which communicate via a complex network of intercellular signaling pathways mediated by surface adhesion molecules, cytokines and their receptors. 8 MC density is highly correlated with the extent of both normal and pathological angiogenesis, such as that in chronic inflammatory diseases and tumors. 9 We have demonstrated that in multiple myeloma and B cell non-Hodgkin's lymphoma there is a striking association between MC and microvessel counts and that both increase in function of tumor progression, as defined by its increasing malignancies grades, 10, 11 while in both benign lymphadenopathies and in B cell non-Hodgkin's lymphoma angiogenesis is highly correlated with the total and MC tryptase-positive counts. 12 Tryptase contained in MC secretory granules is angiogenic both in vitro and in vivo experimental models, and specific tryptase inhibitors suppress this activity. 9 This paper illustrates the correlation between the extent of angiogenesis and the number of tryptase-reactive MC in MDS, comparing them with the whole metachromatic MC.
Materials and methods

Patients
Thirty MDS patients with well-preserved bone marrow biopsy specimens suitable for staining and estimation of microvessel density were selected and were grouped according to the International Prognostic Scoring System (IPSS) for MDS in four risk-based subgroups. 13 Ten patients had low-risk MDS, six patients intermediate-1 risk, four patients intermediate-2 risk and 10 patients poor risk MDS. There was no selection of patients other than mentioned above and from the selected patients none was excluded. Control subjects were 10 patients with anemia due to iron or vitamin B12 deficiencies (n = 8) or with leukocytosis due to acute bacterial infectious (one cholecystitis, and one pyelonephritis) whose diagnosis was not an immediate inference, and required several tests, including bone marrow biopsy. We have shown that patients of this type display very little, if not absent, bone marrow angiogenesis and form a suitable reference group to compare multiple myeloma and monoclonal gammopathy of undetermined significance. 3, 4 Their bone marrow was defined as normal according to routine examination by a pathologist and they displayed no clinical evidence of a malignant condition.
The bone marrow samples from patients and controls retrieved were a mix of needle and true-cut biopsies fixed in formaldehyde and embedded in paraffin. The samples used for diagnosis were examined.
Immunohistochemistry
Two murine monoclonal antibodies (MAbs) against the endothelial cell marker CD31 (MAb 1A10) and tryptase (MAb AA1, Dako, Glostrup, Denmark) were used. Briefly, 4-m thick sections were collected on 3-amino-propyl-triethoxysilane coated slides, deparaffinized with the xylene-ethanol sequence, rehydrated in a graded ethanol scale and in TRISbuffered saline (TBS, pH 7.6), and incubated overnight at 4°C with 1A10 (1:25 in TBS) and AA1 (1:1500 in TBS), after prior antigen retrieval by enzymatic digestion with Ficin (Sigma, St Louis, MO, USA), in a pressure cooker for 90 s in EDTA buffer, pH 8 for CD31 and for 30 min at room temperature for tryp-tase. The immunoreaction was performed with the streptavidin-peroxidase complex (LSAB2, Dako) and with alkakine phosphatase anti-alkaline phosphatase (APAAP, Dako) and Fast Red as chromogen for tryptase, and 3,3Ј diaminobenzidine tetrahydrochloride (Dako) 5% as chromogen for CD31, followed by hematoxylin counterstaining. An unrelated monoclonal IgG1 produced by the P3X63/Ag8 mouse secretory myeloma replacing the MAbs served as the negative control. 14 
Microvessel counts
These were simultaneously assessed without knowledge of the final pathological diagnosis by two investigators with a double-headed light microscope (Axioplan II; Zeiss, Oberkochen, Germany). Four to six × 200 fields covering almost the whole of each of four sections per sample were examined with a 144-intersection point square reticulum (0.78 mm 2 ) inserted in the eyepiece. Care was taken to select microvessels, ie capillaries and small venules, from all the CD31-stained vessels. They were identified as transversally sectioned tubes with a single layer of endothelial cells, either with or without a thin basement membrane. Each assessment was agreed upon in turn. Microvessels were counted with a planimetric pointcount method with slight modifications: 10 only microvessels transversally cut occupying the reticulum points were counted. As the microvessel diameter was smaller than the distance between adjacent points, only one transversally sectioned microvessel could occupy a given point. Microvessels transversally sectioned outside the points and those longitudinally or tangentially sectioned were omitted. Therefore, it was sufficiently certain that a given microvessel was counted only once, even in the presence of several of its section planes. As almost the entire section was analyzed per sample, and as transversally sectioned microvessels hit the intersection points randomly, the method produced objective counts. Means ± 1 standard deviation (s.d.) and medians were determined for each section, sample and group of samples.
MC counts
MC were highlighted in every second section adjacent to that stained for microvessels with 0.5% aqueous solution of toluidine blue (Merck, Darmstadt, Germany), counted in six to eight × 250 fields, covering almost the whole section, inside a square reticulum (0.25 mm 2 ), and calculated as means (1 s.d. and median for each group of samples). The MC were stained with tryptase in every third section and counted as above.
Electron microscopy
Small (approximately 1-mm 3 ) tissue pieces were fixed in 3% glutaraldehyde in 0.1 M phosphate buffered saline (PBS) for 3 h, washed in the same buffer for 12 h, post-fixed in 1% osmium tetroxide, dehydrated in graded ethanols and embedded in Epon 812. Ultrathin sections were cut with a diamond knife on a LKB ultratome, stained with uranyl acetate followed by lead citrate, and examined in a EM 109 Zeiss electron microscope.
Leukemia
Statistics
The significance of changes in the counts of microvessels and MC (both total and tryptase-reactive MC) was assessed with parametric (Fisher's test) and non-parametric (Kruskal-Wallis test) analysis of variance, followed by the Duncan (t), Bonferroni (t) and Wilcoxon tests to compare groups two by two. Correlations between counts were assessed with Pearson's (r) coefficient and simple regression analysis. The chi-square test was split into the linear and the residual component according to Cochran. Data were computed with the Statistical Analysis Software (SAS Institute, Cary, NC, USA). Table 1 shows the microvessel and total tryptase-positive MC counts on adjacent tissue sections selected from 30 patients affected by MDS grouped according to the IPSS for MDS in three refined risk-based cytogenetic subgroups (good, intermediate and poor). 13 There are significant differences (chi-square = 35.4, df = 3, P Ͻ 0.001; F = 37.4, P Ͻ 0.001) between the three subgroups concerning the microvessel density. The microvessel counts showed a significant increase in intermediate subgroup over good subgroup (P Ͻ 0.001), yet another in the poor subgroup over intermediate subgroup (P Ͻ 0.001). The MC counts were also significantly different between the three subgroups (chi-square = 39.5, df = 3, P Ͻ 0.001; F = 40.2, P Ͻ 0.001). The intergroups comparisons showed that the counts of MC as total methachromatic cell and tryptase-positive populations were again significantly higher in the intermediate prognosis subgroup than in the good subgroup (P Ͻ 0.001), still higher in the poor subgroup over the intermediate subgroup (P Ͻ 0.001). These differences are also shown in Figure 1 showing the differences in both microvessel (a, b) and MC (c, d) density between the subgroup with good prognosis (panels a, c), and the subgroup with poor prognosis (panels b, d). MC were generally scattered throughout the neoplastic tissue and within the interstitial stroma, where they rested near or around the blood capillaries.
Results
At the ultrastructural level, MC with the semilunar aspect of granules ( Figure 1e ) were recognizable. This reflects the slow, chronic release of mediators in response to a moderate, progressive, degranulatory stimulus.
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Table 1
Tissue density of microvessels and mast cells as entire metachromatic and tryptase-positive cell populations 
Discussion
This paper shows that angiogenesis in MDS, measured as microvessel counts, is highly correlated with total metachromatic and tryptase-positive MC counts and that both parameters increase simultaneously with tumor progression.
MC release a variety of factors known to enhance angiogenesis, namely heparin and histamine, 15, 16 a variety of cytokines, such as transforming growth factor-beta, tumor necrosis factor-␣, 17 interleukin-8, 18 basic fibroblast growth factor or fibroblast growth factor-2 (FGF-2) 19 and vascular endothelial growth factor (VEGF) 20 implicated in normal, as well as tumorassociated angiogenesis. Blair et al 21 have shown that tryptase released by MC plays an important role in neovascularization. Direct addition of tryptase to microvascular endothelial cells cultured on Matrigel caused a pronounced increase of capillary growth, which was suppressed by specific tryptase inhibitors and tryptase directly induced endothelial cell proliferation in a dose-dependent fashion. Moreover, tryptase activates latent metalloproteinases and plasminogen activator, 22 which degrade the extracellular matrix, where angiogenic cytokines, such as FGF-2, are stored. 23 MC are strikingly associated with angiogenesis in tumors, namely hemangioma, carcinomas, lymphoma and multiple myeloma, [10] [11] [12] where they are preferentially accumulated in peripheral areas and within the surrounding connective tissue, and rest near or around blood or lymphatic vessels. MC are recruited and activated via several factors secreted by tumor cells: the c-kit receptor, FGF-2, VEGF and platelet-derived endothelial cell growth factor. 9 Increased plasma levels of FGF-2 and VEGF and an increased VEGF expression in bone marrow megakaryocytes have been reported in MDS. 6 Furthermore, it has been demonstrated in MDS that the microvessel density correlates with blast percentage overexpressing VEGF associated with the co-expression of the VEGF receptor-1 (VEGFR-1) or -2 (VEGFR-2). 24 In line with other reports showing a close relationship between increased number of tryptase-positive MC and the progression of a tumor, 12, 25, 26 our data suggest that tryptasepositive MC may intervene in the angiogenic response in MDS. Furthermore, tumor-derived FGF-2 may have pleiotropic influences, first on tumor invasion, by elevating proteolytic enzymes, 27 second on angiogenesis, by paracrine stimulation of endothelial cell growth, 28 and third on recruitment and activation of MC, which express the FGF-2 receptor. 29 MC, in turn, secrete FGF-2 stored in their secretory granules, which further stimulates endothelial cell growth and amplifies the FGF-2 paracrine stimulatory loop on angiogenesis.
As concerns the ultrastructural features of MC, the semilunar, or partial degranulating appearance of the secretory granules of these MC, unlike the IgE-mediated massive degranulation which occurs during the immediate hypersensitivity reactions, is typical of slow degranulation, taking place in delayed hypersensitivity reactions and chronic inflammatory processes. 30 In tumors, such as MDS, this semilunar appearance may correspond to a slow, but progressive release of angiogenic factors, due to chronic and progressive stimulation of MC degranulation.
Recent studies indicate that anti-angiogenic therapy is highly promising in certain hematological malignancies, such as multiple myeloma. 31 Current treatment of MDS remains problematic. Anti-angiogenic compounds such as thalidomide, a drug which inhibits angiogenesis induced by FGF-2 and VEGF have been successfully utilized in the treatment of MDS. 32 Thalidomide has a number of other anti-tumoral properties, including alterations of adhesion molecules expression, modulation of tumor necrosis factor-␣ production and enhancement of cell-mediated immunity by direct co-stimulation of T cells (reviewed in Ref. 33 ).
In conclusion, our data suggest that the tryptase in the secretory granules of MC, in combination with other granule-associated molecules, such as FGF-2 and VEGF, may contribute to the angiogenesis in MDS.
